In:
Clinical Endocrinology, Wiley, Vol. 7, No. s1 ( 1977-12)
Abstract:
Thirty‐five patients with bone disease and chronic renal failure (twenty‐four on maintenance haemodialysis) were treated for 7–39 months with lα‐hydroxyvitamin D 3 , 2–25 μg daily by mouth. Symptoms (bone pain and muscle weakness) and radiographic appearances improved and plasma alkaline phosphatase returned to normal in the majority of patients (87, 76 and 75% respectively). In contrast, histological appearances in bone improved in only 46% twenty‐three patients from whom paired biopsies were available, and this change was not greatly different from that seen in a comparable group of untreated patients. Significant correlations were noted in individual patients between the changes in symptoms, X‐rays, plasma alkaline phosphatase and immunoreactive parathyroid hormone and these, in turn, were related to histological changes in bone, although these latter changes were often small. It is concluded that lα‐hydroxyvitamin D 3 is a useful new drug in the treatment of renal bone disease, but that the evaluation of the response depends critically on the method of assessment used.
Type of Medium:
Online Resource
ISSN:
0300-0664
,
1365-2265
DOI:
10.1111/cen.1977.7.issue-s1
DOI:
10.1111/j.1365-2265.1977.tb03361.x
Language:
English
Publisher:
Wiley
Publication Date:
1977
detail.hit.zdb_id:
2004597-9
Permalink